All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: ABC294640
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Opaganib, a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, administered at 250mg/kg, showed a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome – a preclinical animal model designed to measure thrombotic risks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
The global Phase 2/3 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a pre-scheduled safety review by an independent Data and Safety Monitoring Board.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has completed enrollment of the last patient in the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2020
Details:
Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthens manufacturing capabilities and capacity, in preparation for potential emergency use applications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 13, 2020
Details:
Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthens manufacturing capabilities and capacity, in preparation for potential emergency use applications .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
The ongoing global Phase 2/3 study with orally-administered opaganib in patients with severe COVID-19 is approved in Italy, the UK, Russia, Israel, Mexico and Brazil; 16 clinical sites initiated globally to date.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
The Phase 2/3 study is set to enroll up to 270 patients with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen. Subjects will be randomized at a 1:1 ratio to receive either opaganib or placebo, along with standard-of-care therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
RedHill Biopharma has initiated a global Phase 2/3 clinical study evaluating opaganib (Yeliva®) in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia requiring treatment with supplemental oxygen.